2010
While teaching at Thailand’s prestigious Mahidol University, Dr. Bhakdi develops a powerful new cell separation method for use in tropical disease diagnostics and goes on to found the university’s first-ever spin-off company.

2016
After introducing a new method of detecting and visualising atypical cells in common body liquids, X-ZELL comes out of stealth mode and is invited to join the world’s leading accelerator program, Y Combinator.

2018
X-ZELL enters into a collaboration with Singapore-based Diagnostics Development (DxD) Hub, a national research and development initiative to fast-track the commercialisation of ground-breaking medical technology.

2019
X-ZELL’s new global head office opens in Singapore, specialising in the optimisation and digitization of cytopathological testing. Next to conventional body liquids, the company’s focus is on blood as a new diagnostic data source.

2020
X-ZELL is ranked second-most innovative healthcare start-up in the world in a Galen Growth ranking and wins the coveted MedTech Innovator APAC award as well as the Startup SG Founder grant.

2021
X-ZELL opens its first European office in Germany and wins the Abstract Award at the European Congress of Cytology. A landmark trial focusing on the early detection of clinically significant prostate cancer from blood begins in Singapore.

2022
X-ZELL collaborates with a leading German cytopathology centre to introduce Cryoimmunostaining™ and digital on-screen analysis into routine cytology as a tool to efficiently analyse common body fluids.

X-ZELL PITCH – Why early cancer detection is possible today, and how we will bring it to the world - Video